A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuria

Metabolism: Clinical and Experimental

Volumn 56, Issue 11, 2007, Pages 1453-1457

  Weinrauch, Larry A ^a,b,c,d   Burger, Andrew J ^b,d   Aepfelbacher, Franz ^b,d   Lee, Annette T ^e   Gleason, Ray E ^d   D'Elia, John A ^a,b,d  

^a JOSLIN DIABETES CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MOUNT AUBURN HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BLOOD CLOTTING FACTOR 7; CARBON DIOXIDE; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

AMBULATORY MONITORING; ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOPPLER ECHOCARDIOGRAPHY; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART MASSAGE; HEART RATE VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; KIDNEY DISEASE; KIDNEY FUNCTION; MULTICENTER STUDY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VISCOSITY;

CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; PILOT PROJECTS; PROTEINURIA;

EID: 35248831730     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.05.016     Document Type: Article

References (22)

1. Aoki T.T., Vlachokosta F.V., Foss M.C., and Meistas M.T. Evidence for restoration of hepatic glucose processing in type I diabetes mellitus. J Clin Invest 71 (1983) 837-839
2. Paolisso G., Scheen A.J., Giugliano D., Sgambato S., Albert A., Varrichio M., et al. Pulsatile insulin delivery has greater metabolic effects than continuous hormone administration in man: importance of pulse frequency. J Clin Endocrinol Metab 72 (1991) 607-615
3. Paolisso G., Sgambato S., Giunta R., Varrichio M., and D'Onofrio F. Pulsatile rather than continuous glucagon infusion leads to greater metabolic derangements in insulin-dependent diabetic subjects. Diabete Metab 16 (1990) 42-47
4. Maiter D., Underwood L.E., Maes M., Davenport M.L., and Ketelslegers J.M. Different effects of intermittent and continuous growth hormone administration on serum somatostatin-C/insulin-like growth factor 1 and liver growth hormone receptors in hypophysectomized rats. Endocrinology 123 (1988) 1053-1059
5. Pal B.R., Phillips P.E., Matthews D.R., and Dunger D.B. Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin-dependent) diabetes mellitus. Diabetelogia 35 (1992) 542-549
6. Aoki T.T., Benbarka M.M., Okimura M.C., et al. Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus. Lancet 342 (1993) 525-528
7. Aoki T.T., Grecu E.O., and Arcangeli M.A. Chronic intermittent intravenous insulin therapy corrects orthostatic hypotension of diabetes. Am J Med 99 (1995) 683-684
8. Dailey G.E., Boden G.H., Creech R.H., Johnson D.G., Gleason R.E., Kennedy F.P., et al. Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism 49 (2000) 1491-1495
9. Korner A., Eklof A.C., Celsi G., and Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 43 (1994) 629-633
10. Wohl P., Wohl P., Girman P., and Pelikanova T. Inflexibility of energy substrate oxidation in type 1 diabetic patients. Metabolism 53 (2004) 655-659
11. Perseghin G., Lattuada G., de Cobelli F., Esposito A., Constantino F., Canu T., et al. Reduced intrahepatic fat content is associated with increased whole body lipid oxidation in patients with diabetes. Diabetologia 48 (2005) 2615-2621
12. Avignon A., Lapinski H., Rabasa-Lhoret R., Caubel C., Boniface H., and Monnier L. Energy metabolism and substrates oxidative patterns in type 2 diabetic patients treated with sulphonylurea alone or in combination with metformin. Diabetes Obes Metab 2 (2000) 229-235
13. Pugliese G., Pricci F., Romeo G., Pugliese F., Mene P., Giannini S., et al. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 46 (1997) 1881-1887
14. Wendt T., Tanji N., Guo J., Hudson B.I., Bierhaus A., Ramasamy R., et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14 (2003) 1383-1395
15. Shapiro A.M.J., Ricordi C., Hering B.J., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355 (2006) 1318-1330
16. Weinrauch L.A., Kennedy F.J., Burger A.J., Gleason R.E., Keough J., and D'Elia J.A. Prospective evaluation of autonomic dysfunction in aggressive management of diabetic microangiopathy. Am J Hypertens 12 (1999) 1135-1139
17. Burger A.J., Weinrauch L.A., D'Elia J.A., and Aronson D. Effect of glycemic control on heart rate variability in type 1 diabetic patients with cardiac autonomic neuropathy. Am J Cardiol 84 (1999) 669-687
18. Aepfelbacher F., Yeon S.B., Weinrauch L.A., D'Elia J., and Burger A.J. Effect of improved glycemic control on left ventricular structure and function in patients with type 1 diabetes mellitus. Int J Cardiol 94 (2004) 47-51
19. Weinrauch L.A., Burger A., Gleason R.E., Lee A.T., and D'Elia J.A. Left ventricular mass reduction in type 1 diabetic patients with nephropathy. J Clin Hypertens 7 (2005) 159-164
20. Weinrauch L.A., Burger A., Aronson D., Gleason R.E., Lee A.T., and D'Elia J.A. Regression of left ventricular hypertrophy in diabetic nephropathy: loss of parasympathetic function predicts response to treatment. J Clin Hypertens 8 (2006) 330-335
21. D'Elia J., Weinrauch L., Gleason R., Lipinska I., Keough J., Pendse S., et al. Fibrinogen and factor VII levels improve with glycemic control in type 1 diabetic patients with microvascular complications. Arch Int Med 161 (2001) 98-101
22. Roshon B., Tofler G., Weinrauch L., Gleason R., Keough J., Lipinska I., et al. Improved glycemic control and platelet function abnormalities in diabetic patients with microvascular disease. Metabolism 49 (2000) 88-91